id: NEW:baclofen_pharmacotherapy_aud_to_NEW:aud_relapse
name: Baclofen Pharmacotherapy for Alcohol Use Disorder â†’ Alcohol Use Disorder Relapse
from_node:
  node_id: NEW:baclofen_pharmacotherapy_aud
  node_name: Baclofen Pharmacotherapy for Alcohol Use Disorder
to_node:
  node_id: NEW:aud_relapse
  node_name: Alcohol Use Disorder Relapse
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Baclofen administered at doses up to 50-60 mg/day for AUD relapse prevention'
- 'Step 2: GABA-B receptor modulation to reduce alcohol reinforcement and craving'
- 'Step 3: Assessment of relapse as binary treatment outcome'
evidence:
  quality_rating: A
  n_studies: 14
  primary_citation: 'Kazumasa Kotake et al. 2025. "Optimal Dose of Baclofen for the Treatment of Alcohol
    Use Disorder: A Systematic Review and Dose-Response Meta-analysis.." https://doi.org/10.1007/s40263-025-01188-2'
  supporting_citations:
  - Additional citations require full-text access - meta-analysis included 14 randomized controlled trials
  - Studies identified through Cochrane, EMBASE, MEDLINE via PubMed, PsycINFO databases
  - ClinicalTrials.gov and International Clinical Trials Registry Platform searches conducted April 2024
  doi: 10.1007/s40263-025-01188-2
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Baclofen up to 50-60 mg/day did not significantly affect relapse rates in this meta-analysis,
  despite improving percent days abstinent and reducing craving. This suggests that relapse is a complex
  outcome influenced by multiple factors beyond medication effects.
quantitative_effects:
  sample_size: 1344
structural_competency:
  equity_implications: Relapse prevention in AUD involves multiple structural factors including social
    support networks, housing stability, employment, access to continued care, and reduction in environmental
    triggers. Medication alone may be insufficient to prevent relapse without addressing these broader
    structural determinants. Comprehensive AUD treatment should integrate pharmacotherapy with social
    services and environmental modifications.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.903803'
  extraction_confidence: high
  prompt_version: 2.1-canonical-validated
